Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05925569 · ClinicalTrials.gov registry record · NA
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
A NA study of Hypertension and Resistant Hypertension, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- NA
- Development phase
- 12,501
- Enrollment target
- 1
- Study location
NCT05925569: Active NA study of Hypertension and Resistant Hypertension, sponsored by Brigham and Women's Hospital.
NCT05925569 is a NA study of Hypertension and Resistant Hypertension that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 12,501 participants, above the 3,481-participant average among 470 other Hypertension trials with a reported enrollment target (259% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05925569, a NA study of Hypertension and Resistant Hypertension, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12,501 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary aldosteronism (PA) is common but rarely recognized cause of hypertension that carries excess cardiovascular and renal risk and has approved targeted treatments. Despite current clinical guidelines that recommend screening in a defined set of high-risk populations, less than 5% of eligible patients are ever screened for PA. This study aims to evaluate the impact of a computer decision support Best Practice Advisory (BPA) alert on rates of screening for PA in guideline-eligible patients, referral to specialist PA care, and treatment with mineralocorticoid receptor antagonists.
Primary Outcome
The primary outcome is the frequency of aldosterone/renin laboratory testing orders by providers.
Conditions Studied
Interventions
- OTHER Best Practice Advisory Computerized Alert
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,501 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2029-12-31 |
| Phase | NA |
What the registry record for NCT05925569 still lists
NCT05925569 is an interventional study that assigns participants to a tested intervention. Its 12,501 participants enrollment target places it among the larger protocols in the corpus, above the 3,481-participant average among 470 other Hypertension trials with a reported enrollment target (259% higher).
The record links to 6 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Best Practice Advisory Computerized Alert is the first listed.
NCT05925569 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05925569 about?
NCT05925569 is a clinical study titled "Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension". Primary aldosteronism (PA) is common but rarely recognized cause of hypertension that carries excess cardiovascular and renal risk and has approved targeted treatments. Despite current clinical guidelines that recommend screening in a defined set of high-risk populations, less than 5% of eligible pa...
What is the current status of trial NCT05925569?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12,501 participants. The study started on 2024-03-13. Estimated completion is 2029-12-31.
What conditions does trial NCT05925569 study?
This clinical trial studies the following conditions: Hypertension, Resistant Hypertension, Primary Aldosteronism, Hyperaldosteronism, Mineralocorticoid Excess.
What interventions are being tested in trial NCT05925569?
The interventions under investigation include: Best Practice Advisory Computerized Alert (OTHER).
Who is sponsoring clinical trial NCT05925569?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05925569 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05925569's enrollment target sits among peer trials
12,501 16th of 470 higher than 455 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04888832 · 12,500 participants · NA
The Effect of Work Requirements in SNAP in Virginia
- NCT05452941 · 12,500 participants
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- NCT07069556 · 12,500 participants
ColoSense Post-Approval Study
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI